SR 59230A
SIGMA/S8688 - ≥98% (HPLC), powder
Synonym: 3-
CAS Number: 174689-39-5
Empirical Formula (Hill Notation): C21H27NO2 · C2H2O4
Molecular Weight: 415.48
MDL Number: MFCD00940163
Linear Formula: C21H27NO2 · C2H2O4
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | powder |
| InChI | 1S/C21H27NO2.C2H2O4/c1-2- |
| InChI key | XTBQNQMNFXNGLR-MKSBGGEFSA |
| originator | Sanofi Aventis |
| Quality Level | 100 ![]() |
| SMILES string | OC(=O)C(O)=O.CCc1ccccc1OC |
| solubility | DMSO: >10 mg/mL |
| H2O: insoluble |
| Application: | SR 59230A was used in the identification of β-adrenoceptors in rat aorta.3 It was tested as a potential therapeutic agent in improving cardiac function in rat model of heart failure.4 |
| Biochem/physiol Actions: | SR 59230A is a β3-adrenoceptor antagonist. It has high affinity for the β3 adrenoceptors occurring in human gut that affect the function of human colonic circular smooth muscle.1 It is reported that SR 59230A inhibits the Kir2.1-2.3 cardiac potassium channels.2 |
| Features and Benefits: | This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |

